Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 | PTC Therapeutics | HOLD $46 | ― | -4.20% | Assigned | TD Cowen Keeps Their Hold Rating on PTC Therapeutics (PTCT) | |||
| United States Steel | HOLD $35→$40 | ― | 0.00% | Reiterated | Analysts Offer Insights on Materials Companies: United States Steel (NYSE: X) and Origin Materials (NASDAQ: ORGN) | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $8.5 | ― | 1.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $117 | ― | 5.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $80 | ― | 14.10% | Reiterated | ||||
 | BridgeBio Pharma | BUY $48 | ― | -4.40% | Reiterated | Scotiabank Keeps Their Buy Rating on BridgeBio Pharma (BBIO) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $13.5 | ― | 10.70% | Reiterated | ||||
| Kinder Morgan | HOLD $26 | ― | 1.20% | Reiterated | Scotiabank Sticks to Its Hold Rating for Kinder Morgan (KMI) | |||
| Halozyme | BUY $77 | ― | -1.60% | Assigned | Halozyme: Undervalued Growth Potential Amidst Strong Core Business and Future Opportunities | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $149→$143 | ― | 15.70% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $34 | ― | 11.10% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $480 | ― | 18.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $180 | ― | 8.40% | Initiated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $60 | ― | 8.40% | Initiated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $52 | ― | 8.40% | Initiated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $40 | ― | 8.40% | Initiated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY | ― | 8.00% | Upgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $461 | ― | 11.60% | Reiterated | ||||
| Lineage, Inc. | HOLD $61 | ― | -0.60% | Initiated | Lineage initiated with a Neutral at Exane BNP Paribas | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $100→$108 | ― | 10.10% | Reiterated | ||||
| BioMarin Pharmaceutical | BUY $115 | ― | -9.90% | Reiterated | BioMarin Pharmaceutical: Strategic Initiatives and Promising Pipeline Drive Buy Rating | |||
| Sarepta Therapeutics | BUY $200 | ― | -9.90% | Reiterated | Sarepta Therapeutics: A Buy Rating Backed by Strong Elevidys Performance and Growth Prospects | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $385→$180 | ― | 15.30% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $90→$70 | ― | 19.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD | ― | 6.20% | Initiated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $80.9→$83.98 | ― | 4.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $1,482→$1,534 | ― | 15.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $220→$150 | ― | 19.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $128→$130 | ― | 15.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $133→$129 | ― | 15.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $106→$114 | ― | 15.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $85→$88 | ― | 15.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $80→$82 | ― | 15.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $80→$81 | ― | 15.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $90→$70 | ― | 19.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $57→$52 | ― | 8.10% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $18→$19 | ― | 15.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD | ― | 6.40% | Downgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD | ― | 8.50% | Downgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $105 | ― | 15.30% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $140 | ― | 9.90% | Reiterated | ||||
 | Astria Therapeutics | BUY $22 | ― | -3.50% | Assigned | Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (NASDAQ: ATXS) and Mediwound (NASDAQ: MDWD) | |||
| Sarepta Therapeutics | BUY $202 | ― | -8.60% | Reiterated | Sarepta Therapeutics Surpasses Sales Expectations with Strong Elevidys Performance and Positive FY:25 Outlook | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $120 | ― | 26.30% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $96→$95 | ― | 16.20% | Reiterated | ||||
| Cencora | BUY $285 | ― | -7.40% | Reiterated | Evercore ISI Sticks to Their Buy Rating for Cencora (COR) | |||
 | Coca-Cola Europacific Partners | BUY $82 | ― | -1.70% | Reiterated | Evercore ISI Keeps Their Buy Rating on Coca-Cola Europacific Partners (CCEP) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $65 | ― | 11.00% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $205→$220 | ― | 7.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $120 | ― | 14.70% | Reiterated |
Rows:
